Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes

다국어 초록 (Multilingual Abstract)

Psoriasis is a chronic, recurrent, heterogeneous, cutaneous inflammatory skin disease for which there is no cure. It affects approximately 7.5 million people in the United States. Currently, several biologic agents that target different molecules implicated in the pathogenic processes of psoriasis are being assessed in diverse clinical studies. However, relapse usually occurs within weeks or months, meaning there is currently no cure for psoriasis. Therefore, recent studies have discovered diverse new potential treatments for psoriasis: inhibitors of bacteria such as Staphylococcus aureus, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and neuropilin 1 (NRP1). A promising approach that has recently been described involves modifying antimicrobial peptides to develop new cutaneous anti-bacterial agents that target inflammatory skin disease induced by Staphylococcus. Increased expression of TRAIL and its death receptors DR4 and DR5 has been implicated in the pathogenesis of plaque psoriasis. In addition, TRAIL has the ability to inhibit angiogenesis by inducing endothelial cell death and by negative regulation of VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions. Since NRP1 regulates angiogenesis induced by multiple signals, including VEGF, ECM and semaphorins, and also initiates proliferation of keratinocytes through NF-kB signaling pathway in involved psoriatic skin, targeting NRP1 pathways may offer numerous windows for intervention in psoriasis. In this review, we will focus on the current knowledge about the emerging role of synthetic antimicrobial peptides, TRAIL and NRP1 blocking peptides in the pathogenesis and treatment of psoriasis.

참고문헌 (Reference)

1 Caldarola G, "Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): a possible pathogenic role in chronic plaque psoriasis" 151 : 17-24, 2016

2 Secchiero P, "Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis" 15 : 42-48, 2008

3 Waisman A, "To be 17 again--anti-interleukin-17 treatment for psoriasis" 366 : 1251-1252, 2012

4 Menter A, "The status of biologic therapies in the treatment of moderate to severe psoriasis" 84 (84): 14-24, 2009

5 Leung DY, "The role of superantigens in human diseases: therapeutic implications for the treatment of skin diseases" 139 (139): 17-29, 1998

6 Kurd SK, "The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004" 60 : 218-224, 2009

7 Albanesi C, "The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis" 9 : 1549-, 2018

8 Shbeeb M, "The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991" 27 : 1247-1250, 2000

9 Javitz HS, "The direct cost of care for psoriasis and psoriatic arthritis in the United States" 46 : 850-860, 2002

10 Di Cesare A, "The IL-23/Th17 axis in the immunopathogenesis of psoriasis" 129 : 1339-1350, 2009

11 Lowes MA, "The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses" 34 : 174-181, 2013

12 Plant D, "The CX3CL1-CX3CR1 system and psoriasis" 15 : 900-903, 2006

13 Ariza ME, "Targeting IL-17 in psoriasis:from cutaneous immunobiology to clinical application" 146 : 131-139, 2013

14 Na HJ, "TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions" 17 : 179-194, 2014

15 Kolodkin AL, "Steering clear of semaphorins: neuropilins sound the retreat" 19 : 1159-1162, 1997

16 Ezepchuk YV, "Staphylococcal toxins and protein A differentially induce cytotoxicity and release of tumor necrosis factor-alpha from human keratinocytes" 107 : 603-609, 1996

17 Nestle FO, "Skin immune sentinels in health and disease" 9 : 679-691, 2009

18 Rich P, "Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study" 168 : 402-411, 2013

19 Albanesi C, "Resident skin cells in psoriasis:a special look at the pathogenetic functions of keratinocytes" 25 : 581-588, 2007

20 Zaba LC, "Resident and "inflammatory"dendritic cells in human skin" 129 : 302-308, 2009

21 Dannappel M, "RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis" 513 : 90-94, 2014

22 Saito N, "RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis" 91 : 79-86, 2018

23 Boehncke WH, "Pulling the trigger on psoriasis" 379 : 777-, 1996

24 Wagner EF, "Psoriasis: what we have learned from mouse models" 6 : 704-714, 2010

25 Boehncke WH, "Psoriasis" 386 : 983-994, 2015

26 Perera GK, "Psoriasis" 7 : 385-422, 2012

27 Lowes MA, "Pathogenesis and therapy of psoriasis" 445 : 866-873, 2007

28 Albanesi C, "Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs" 11 : 210-227, 2010

29 Williams SC, "New biologic drugs get under the skin of psoriasis" 18 : 638-, 2012

30 Saban MR, "Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment" 299 : F1245-F1256, 2010

31 Gluzman-Poltorak Z, "Neuropilin-2is a receptor for the vascular endothelial growth factor (VEGF)forms VEGF-145 and VEGF-165 [corrected]" 275 : 18040-18045, 2000

32 Chen H, "Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III" 19 : 547-559, 1997

33 Giger RJ, "Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity" 21 : 1079-1092, 1998

34 Soker S, "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor" 92 : 735-745, 1998

35 Gu C, "Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development" 5 : 45-57, 2003

36 Schwarz Q, "Neuropilin, you gotta let me know:should I stay or should I go?" 4 : 61-66, 2010

37 Lampropoulou A, "Neuropilin regulation of angiogenesis" 42 : 1623-1628, 2014

38 He Z, "Neuropilin is a receptor for the axonal chemorepellent Semaphorin III" 90 : 739-751, 1997

39 Gudjonsson JE, "Mouse models of psoriasis" 127 : 1292-1308, 2007

40 Nakamura F, "Molecular basis of semaphorin-mediated axon guidance" 44 : 219-229, 2000

41 Arakawa A, "Melanocyte antigen triggers autoimmunity in human psoriasis" 212 : 2203-2212, 2015

42 Zasloff M, "Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor" 84 : 5449-5453, 1987

43 Ruíz-González V, "Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13" 48 : 846-854, 2009

44 Büchau AS, "Innate immunity and antimicrobial defense systems in psoriasis" 25 : 616-624, 2007

45 Peternel S, "Increased expression of TRAIL and its death receptors DR4and DR5 in plaque psoriasis" 303 : 389-397, 2011

46 Sabat R, "Immunopathogenesis of psoriasis" 16 : 779-798, 2007

47 Ghoreschi K, "Immunopathogenesis and role of T cells in psoriasis" 25 : 574-580, 2007

48 van der Fits L, "Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis" 182 : 5836-5845, 2009

49 Gagnon ML, "Identification of a natural soluble neuropilin-1that binds vascular endothelial growth factor: in vivo expression and antitumor activity" 97 : 2573-2578, 2000

50 Zaba LC, "Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis" 125 : 1261-1268, 2010

51 Ma HL, "IL-22is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation" 118 : 597-607, 2008

52 Tossi A, "Host defense peptides: roles and applications" 6 : 1-3, 2005

53 Henno A, "Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis" 57 : 162-169, 2010

54 Menter A, "Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics" 58 : 826-850, 2008

55 Rossignol M, "Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms" 70 : 211-222, 2000

56 Parker MW, "Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin" 49 : 4068-4075, 2010

57 McPhee JB, "Function and therapeutic potential of host defence peptides" 11 : 677-687, 2005

58 Paller AS, "Etanercept treatment for children and adolescents with plaque psoriasis" 358 : 241-251, 2008

59 Leonardi CL, "Etanercept as monotherapy in patients with psoriasis" 349 : 2014-2022, 2003

60 Blanpain C, "Epidermal homeostasis: a balancing act of stem cells in the skin" 10 : 207-217, 2009

61 Papp K, "Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial" 380 : 738-746, 2012

62 Papp KA, "Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study" 167 : 668-677, 2012

63 Wilson NJ, "Development, cytokine profile and function of human interleukin 17-producing helper T cells" 8 : 950-957, 2007

64 Wrone-Smith T, "Dermal injection of immunocytes induces psoriasis" 98 : 1878-1887, 1996

65 Lehrer RI, "Defensins: endogenous antibiotic peptides of animal cells" 64 : 229-230, 1991

66 Dombrowski Y, "Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions" 3 : 82-, 2011

67 Johnson-Huang LM, "Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases" 29 : 247-256, 2009

68 Lande R, "Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis" 6 : 6595-, 2015

69 Ono S, "Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin" 4 : 429-433, 2018

70 Griffiths CE, "Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis" 362 : 118-128, 2010

71 Soker S, "Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain" 271 : 5761-5767, 1996

72 Gu C, "Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165" 277 : 18069-18076, 2002

73 Boman HG, "Cell-free immunity in insects" 41 : 103-126, 1987

74 Papp KA, "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis" 366 : 1181-1189, 2012

75 Koczulla AR, "Antimicrobial peptides: current status and therapeutic potential" 63 : 389-406, 2003

76 Zasloff M, "Antimicrobial peptides of multicellular organisms" 415 : 389-395, 2002

77 Morizane S, "Antimicrobial peptides in the pathogenesis of psoriasis" 39 : 225-230, 2012

78 Leonardi C, "Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis" 366 : 1190-1199, 2012

79 Conrad C, "Animal models of psoriasis and psoriatic arthritis: an update" 8 : 342-347, 2006

80 Henno A, "Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis" 160 : 581-590, 2009

81 Conrad C, "Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis" 13 : 836-842, 2007

82 Henderson CA, "Acute psoriasis associated with Lancefield Group C and Group G cutaneous streptococcal infections" 118 : 559-561, 1988

83 Lai Y, "AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense" 30 : 131-141, 2009

84 Johnson-Huang LM, "A single intradermal injection of IFN induces an inflammatory state in both non-lesional psoriatic and healthy skin" 132 : 1177-1187, 2012

85 Kawasaki T, "A requirement for neuropilin-1 in embryonic vessel formation" 126 : 4895-4902, 1999

86 Leung DY, "A potential role for superantigens in the pathogenesis of psoriasis" 100 : 225-228, 1993

87 Lebwohl M, "A novel targeted T-cell modulator, efalizumab, for plaque psoriasis" 349 : 2004-2013, 2003

88 Krueger GG, "A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis" 356 : 580-592, 2007